Patents-Review.com
ClassID:

21007 ⎘

A61K38/34 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin

Recent Application in this class:
#1
20260151434
2026-06-04

COMPOSITIONS FOR THE TREATMENT OF DISEASE

 #2
20250129118
2025-04-24

MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE

 #3
20240335502
2024-10-10

USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION

 #4
20230167154
2023-06-01

Melanocortin 1 receptor ligands and methods of use

 #5
20230158118
2023-05-25

Use of bremelanotide in patients with controlled hypertension

 #6
20230103704
2023-04-06

HUMAN ANTI-INFLAMMATORY PEPTIDES FOR THE INHALATORY TREATMENT OF INFLAMMATORY PULMONARY ISSUES

 #7
20230101963
2023-03-30

TREATMENT OF MEDICAL INDICATION

 #8
20220362328
2022-11-17

USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION

 #9
20220313789
2022-10-06

TARGETING MELANOCORTIN 3 RECEPTOR FOR TREATMENT/PREVENTION OF EATING, METABOLISM, AND/OR EMOTIONAL DISORDERS

 #10
20220135968
2022-05-05

TREATMENT OF SYNUCLEINOPATHY AND ANIMAL MODELS OF SYNUCLEINOPATHY

 #11
20220062387
2022-03-03

Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages

 #12
20210386832
2021-12-16

Pharmaceutical Compositions And Methods

 #13
20210220444
2021-07-22

Use of bremelanotide in patients with controlled hypertension

 #14
20210101934
2021-04-08

Bovine adrenal medulla peptide 8-22 compounds and methods of use thereof for treating pain

 #15
20210060120
2021-03-04

USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION

 #16
20200360328
2020-11-19

Compositions and methods for treating cancer

 #17
20200254067
2020-08-13

Pharmaceutical compositions and methods

 #18
20200246436
2020-08-06

ALPHA-MSH ANALOGUES USED IN THE TREATMENT OF XERODERMA PIGMENTOSUM

 #19
20200188441
2020-06-18

METHODS AND COMPOSITIONS FOR REDUCING CORNEAL ENDOTHELIAL CELL LOSS

 #20
20200002376
2020-01-02

Melanocortin 1 receptor ligands and methods of use

 #21
20190275117
2019-09-12

Pharmaceutical compositions and methods

 #22
20190216888
2019-07-18

USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION

 #23
20190030134
2019-01-31

Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages

 #24
20180371048
2018-12-27

Fusion protein for alpha-melanocyte stimulating hormone and preparation method and use thereof

 #25
20180360919
2018-12-20

Methods of inducing melanogenesis in a subject

 #26
20180319842
2018-11-08

Compounds and methods for treating pain

 #27
20180140677
2018-05-24

Enhanced melanoma cancer prevention by novel melanotropins

 #28
20180092959
2018-04-05

MEMORY OR LEARNING IMPROVEMENT USING PEPTIDE AND OTHER COMPOSITIONS

 #29
20180085425
2018-03-29

Uses of bremelanotide in therapy for female sexual dysfunction

 #30
20180042985
2018-02-15

Methods of improving behavioral therapies

 #31
20180008676
2018-01-11

Therapy for vitiligo

 #32
20170360896
2017-12-21

INFLAMMATORY DISEASE

 #33
20170349571
2017-12-07

Positive allosteric modulators of human melanocortin-4 receptor

 #34
20170326243
2017-11-16

Methods and systems for treating or preventing cancer

 #35
20170326173
2017-11-16

Brain and neural treatments comprising peptides and other compositions

 #36
20170326063
2017-11-16

Topical systems and methods for treating sexual dysfunction

 #37
20170313756
2017-11-02

Peptide analogs of alpha-melanocyte stimulating hormone

 #38
20170304406
2017-10-26

NEW INDICATION FOR ALPHA-MSH ANALOGUES

 #39
20170281715
2017-10-05

Memory or learning improvement using peptide and other compositions

 #40
20170281672
2017-10-05

Systems and methods for delivery of peptides

 #41
20170274051
2017-09-28

Pharmaceutical compositions and methods

 #42
20170274010
2017-09-28

Immune modulation using peptides and other compositions

 #43
20170218017
2017-08-03

Melanocortin 1 receptor ligands and methods of use

 #44
20160375093
2016-12-29

Pharmaceutical compositions and methods

 #45
20160361354
2016-12-15

IMMUNE MODULATION USING PEPTIDES AND OTHER COMPOSITIONS

 #46
20160324771
2016-11-10

Topical systems and methods for treating sexual dysfunction

 #47
20160263198
2016-09-15

Pharmaceutical compositions and methods

 #48
20160263149
2016-09-15

Pharmaceutical compositions and methods

 #49
20160235819
2016-08-18

Methods of inducing melanogenesis in a subject

 #50
20160158371
2016-06-09

Methods and systems for treating or preventing cancer

 #51
20160158322
2016-06-09

NDP-MSH for treatment of inflammatory and/or neurodegenerative disorders of the central nervous system

 #52
20160158279
2016-06-09

Systems and methods for delivery of peptides

 #53
20160158278
2016-06-09

Brain and neural treatments comprising peptides and other compositions

 #54
20160158277
2016-06-09

Immune modulation using peptides and other compositions

 #55
20160046688
2016-02-18

Peptide analogs of alpha-melanocyte stimulating hormone

 #56
20160045545
2016-02-18

Topical systems and methods for treating sexual dysfunction

 #57
20150290279
2015-10-15

Pharmaceutical compositions and methods

 #58
20150202187
2015-07-23

COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO

 #59
20150174063
2015-06-25

Oral administration of tocilizumab treatment of autoimmune disease

 #60
20150080291
2015-03-19

Short antimicrobial lipopeptides

 #61
20150045719
2015-02-12

Combination of a MC1R receptor agonist and UVB for the treatment and/or prevention of pigmentation disorders

 #62
20150018275
2015-01-15

Methods of improving behavioral therapies

 #63
20150010557
2015-01-08

Method for delivering alpha-melanocyte stimulating hormone mimetibody composition comprising propylene glycol for intranasal administration to the central nervous system

 #64
20140378392
2014-12-25

Uses of bremelanotide in therapy for female sexual dysfunction

 #65
20140371147
2014-12-18

Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders

 #66
20140323394
2014-10-30

Tripeptide KDPT for antiapoptotic treatment

 #67
20140271935
2014-09-18

Methods and systems for treating or preventing cancer

 #68
20140271811
2014-09-18

Topical systems and methods for treating sexual dysfunction

 #69
20140271808
2014-09-18

Systems and methods for delivery of peptides

 #70
20140271807
2014-09-18

Brain and neural treatments comprising peptides and other compositions

 #71
20140271806
2014-09-18

Memory or learning improvement using peptide and other compositions

 #72
20140271804
2014-09-18

Methods and systems for treating or preventing cancer

 #73
20140271800
2014-09-18

Immune modulation using peptides and other compositions

 #74
20140271730
2014-09-18

Immune modulation using peptides and other compositions

 #75
20140072530
2014-03-13

TREATMENT OF HIV

 #76
20130344102
2013-12-26

FORMULATION

 #77
20130203670
2013-08-08

Therapy for vitiligo

 #78
20130184214
2013-07-18

Pharmaceutical compositions and methods

 #79
20120237557
2012-09-20

BIOACTIVE CARBON-NANOTUBE AGAROSE COMPOSITES FOR NEURAL ENGINEERING

 #80
20120225816
2012-09-06

Pharmaceutical compositions of melanocortin receptor ligands

 #81
20120208745
2012-08-16

TREATMENT OF HIV

 #82
20120135923
2012-05-31

Use of Melanocortins to Treat Dyslipidemia

 #83
20120108510
2012-05-03

METHODS OF IMPROVING BEHAVIORAL THERAPIES

 #84
20110263508
2011-10-27

Compositions and methods for including melanogenesis in a subject

 #85
20110206642
2011-08-25

Preventing obesity-related metabolic syndrome with melagonesis

 #86
20110130705
2011-06-02

THERAPY FOR VITILIGO

 #87
20110129462
2011-06-02

Intranasal administration of active agents to the central nervous system

 #88
20110065630
2011-03-17

Use of a octreotide as a therapeutic agent

 #89
20110059891
2011-03-10

Alpha-MSH therapies for treatment of autoimmune disease

 #90
20100204149
2010-08-12

USE OF OCTREOTIDE AS A THERAPEUTIC AGENT

 #91
20100204141
2010-08-12

USE OF BPP-B AS A THERAPEUTIC AGENT

 #92
20100183700
2010-07-22

Implantable pump for protein delivery for obesity control by drug infusion into the brain

 #93
20100120668
2010-05-13

Method of treatment of photodermatoses

 #94
20100113337
2010-05-06

METHOD FOR REDUCING INCIDENCE OR RATE OF DEVELOPMENT OF SKIN CANCERS AND RELATED CONDITIONS

 #95
20100063251
2010-03-11

COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC FATIGUE SYNDROME AND NEURODEGENERATIVE DISEASES

 #96
20090304768
2009-12-10

Gastro-Retentive System for the Delivery of Macromolecules

 #97
20090298915
2009-12-03

TOPICAL DRUG DELIVERY

 #98
20090297444
2009-12-03

Peptide analogs of alpha-melanocyte stimulating hormone

 #99
20090291060
2009-11-26

Treatment of HIV

 #100
20090232866
2009-09-17

Oligopeptides as coating material for medical products

 #101
20090186020
2009-07-23

Melanocortin receptor binding mimetibodies, compositions, methods and uses

 #102
20090136505
2009-05-28

Intranasal Administration of Active Agents to the Central Nervous System

 #103
20090136453
2009-05-28

Methods for treating pain

 #104
20090060868
2009-03-05

Alpha-MSH therapies for treatment of autoimmune disease

 #105
20090017022
2009-01-15

Sulfatases and methods of use thereof

 #106
20080305152
2008-12-11

Methods of inducing melanogenesis in a subject

 #107
20080255033
2008-10-16

Metallopeptide gamma-Melanocyte Stimulating Hormone Compounds

 #108
20080207500
2008-08-28

Medicament

 #109
20080194485
2008-08-14

Detection and Use of Prolylcarboxypeptidase

 #110
20080108574
2008-05-08

MELANOCORTIN RECEPTOR MEDIATED MODULATION OF NEUROGENESIS

 #111
20080004213
2008-01-03

Method of inducing melanogenesis in humans with MC1R variant alleles

 #112
20070172517
2007-07-26

Compositions capable of facilitation penetration across a biological barrier

 #113
20070082843
2007-04-12

Implantable pump for protein delivery for obesity control by drug infusion into the brain

 #114
20070031341
2007-02-08

Methods of delivering therapeutics to the brain

 #115
20060188496
2006-08-24

Intranasal administration of active agents to the central nervous system

 #116
20060178313
2006-08-10

Use of a polypeptide for treatment of pruritus in animals

 #117
20060172922
2006-08-03

Methods for combating ischemic injury to epithelial organ

 #118
20060127400
2006-06-15

Activation of regulatory T cells by alpha-melanocyte stimulating hormone

 #119
20060111300
2006-05-25

Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone

 #120
20060063708
2006-03-23

Composition and method for regulation of body weight and associated conditions

 #121
20060063705
2006-03-23

Use of alpha-MSH and EPO for preventing or treating ischemic conditions

 #122
20060063230
2006-03-23

Sulfatases and methods of use thereof

 #123
20060029563
2006-02-09

Cutanceous metabolic bio-activator

 #124
20060008446
2006-01-12

Methods for treating pain

 #125
20050282739
2005-12-22

Metallopeptide compounds

 #126
20050267280
2005-12-01

Lactone bearing absorbable polymers

 #127
20050232874
2005-10-20

Compound and method of treatment for fungal pathologies of the oral cavity

 #128
20050142078
2005-06-30

Method of stimulation of melanin production and induction of skin tanning

 #129
20050124551
2005-06-09

Use of KPV tripeptide for dermatological disorders

 #130
20050101535
2005-05-12

Use of a synthetic alpha-melanocyte stimulating hormone agonist to decrease steroid induced weight gain

 #131
20050037032
2005-02-17

Composition and method of treatment for urogenital conditions

 #132
20050032678
2005-02-10

Composition and method for regulation of body weight and associated conditions

 #133
20050014696
2005-01-20

Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone

 #134
14196343
2020-02-04

Control of chronic neuropathic pain and allodynia